Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

132.63USD
18 Aug 2017
Change (% chg)

$-0.41 (-0.31%)
Prev Close
$133.04
Open
$132.67
Day's High
$133.78
Day's Low
$132.38
Volume
4,792,761
Avg. Vol
5,558,524
52-wk High
$137.08
52-wk Low
$109.32

Latest Key Developments (Source: Significant Developments)

Capricor Therapeutics retains full rights to CAP-1002 as Janssen Biotech decides not to exercise option
Thursday, 6 Jul 2017 06:30pm EDT 

July 6 (Reuters) - Capricor Therapeutics Inc ::Capricor therapeutics- no payments between capricor and janssen are required to be made in relation to this decision.Capricor therapeutics retains full rights to cap-1002 as janssen biotech, inc. Decides not to exercise option.Capricor therapeutics inc-in connection with decision, collaboration agreement, license option entered into between co and janssen terminated.Capricor therapeutics inc-no payments between capricor and janssen are required to be made in relation to decision.Capricor therapeutics-co to have fully paid-up non-exclusive license under patents controlled by janssen utilized in production of clinical trial materials.Capricor therapeutics-to have non-exclusive license to publish, disclose, use information of janssen utilized in production of clinical trial materials.  Full Article

Depuy Synthes announces U.S. Launch of Viper and Expedium Fenestrated Screw Systems
Thursday, 29 Jun 2017 10:30am EDT 

June 29 (Reuters) - Depuy Synthes::Depuy synthes - announces U.S. Launch of Viper and Expedium Fenestrated screw systems.  Full Article

FDA grants priority review of Xarelto SNDA to reduce risk of recurrent VTE
Wednesday, 28 Jun 2017 08:30am EDT 

June 28 (Reuters) - Janssen::U.S. FDA grants priority review of Xarelto® (rivaroxaban) SNDA for a 10 mg dose to reduce the risk of recurrent venous thromboembolism (VTE).Janssen - ‍U.S. Food and Drug Administration accepted for priority review a supplemental new drug application (SNDA) for Xarelto (rivaroxaban)​.Janssen - ‍SNDA is to include 10 mg once-daily dose for reducing risk of VTE after atleast 6 months of standard anticoagulant therapy​‍​​.  Full Article

Genmab says U.S. FDA approves darzalex in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma
Friday, 16 Jun 2017 01:06pm EDT 

June 16 (Reuters) - Genmab A/S :Genmab announces u.s. fda approval of darzalex(daratumumab) in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma.Genmab - will receive milestone payments totaling $25 million from Janssen in connection with approval & first commercial sale of darzalex under newly expanded label.Genmab - approval and related milestones do not impact financial guidance issued by Genmab on May 10, 2017.  Full Article

J&J completes $30 bln takeover of Actelion
Friday, 16 Jun 2017 01:00am EDT 

June 16 (Reuters) - Actelion Ltd :Johnson & Johnson completes acquisition of Actelion.Actelion announces completion of acquisition of Actelion Ltd by Johnson & Johnson for a total purchase price of approximately $30 billion in cash.  Full Article

Johnson & Johnson announces completion of acquisition of Actelion
Friday, 16 Jun 2017 01:00am EDT 

June 16 (Reuters) - J&J : :Johnson & Johnson announces completion of acquisition of Actelion.Expects transaction to add about $1.3 billion in sales for 2017 and be accretive to 2017 adjusted earnings per share by approximately $0.07.  Full Article

Minerva Neurosciences enters amendment to co-development and license agreement with Janssen Pharmaceutica NV
Wednesday, 14 Jun 2017 04:38pm EDT 

June 14 (Reuters) - Minerva Neurosciences Inc ::Minerva Neurosciences - on June 13, co entered amendment to co-development and license agreement between company and Janssen Pharmaceutica NV.Minerva Neurosciences Inc - amendment to co-development and license agreement related to company's min-202 product candidate.Minerva Neurosciences Inc - pursuant to amendment, minerva will gain global strategic control of development of min-202 to treat insomnia .Minerva Neurosciences Inc - pursuant to amendment janssen will forego its right to royalties on min-202 insomnia sales in Minerva territories.Minerva Neurosciences Inc - Janssen has agreed to make an upfront payment to Minerva of $30 million upon effectiveness of amendment.Minerva Neurosciences Inc - Minerva also entered into a stock repurchase agreement with Johnson & Johnson Innovation-JJDC Inc.Minerva Neurosciences Inc - Janssen has also agreed to make a $20 million payment at start of a phase 3 insomnia trial for min-202.Minerva Neurosciences Inc - Janssen has also agreed to a $20 million payment when 50pct of patients are enrolled in the trial for min-202.Minerva Neurosciences - to repurchase all of about 3.9 million shares of Minerva stock held by Johnson & Johnson Innovation-JJDC Inc at $0.0001 per share.Minerva Neurosciences-Janssen agreed to waive remaining payments due from Minerva for phase 2 development of min-202, which total about $13 million.  Full Article

Metlife names Susan Podlogar Chief Human Resources Officer
Monday, 12 Jun 2017 11:00am EDT 

June 12 (Reuters) - Metlife Inc ::Metlife names new Chief Human Resources Officer.Named Susan Podlogar as Executive Vice President and Chief Human Resources Officer.Podlogar comes to Metlife from Johnson & Johnson.  Full Article

Qualcomm announces agreement with Lifescan Inc
Monday, 12 Jun 2017 07:30am EDT 

June 12 (Reuters) - Qualcomm Inc ::Qualcomm announces agreement with Lifescan Inc, a Johnson & Johnson diabetes care company, to inform patient care with connected blood glucose meters.Qualcomm Inc - companies plan to deploy 2NET solution to select physician offices in fall of 2017, and expand globally in 2018.Qualcomm Inc - announces agreement with Lifescan Inc.  Full Article

Tesaro says Janssen updated clinicaltrials.gov website to reflect janssen had placed temporary enrollment hold in the galahad ‍​
Monday, 12 Jun 2017 06:47am EDT 

June 12 (Reuters) - Johnson & Johnson :Tesaro says on June 9, Janssen updated clinicaltrials.gov website to reflect Janssen had placed temporary enrollment hold in the galahad trial ‍​- SEC filing ‍​.Tesaro says galahad trial is not on clinical hold, temporary enrollment hold is not due to any safety concerns.Tesaro says Janssen anticipates re-opening enrollment for galahad trial soon.  Full Article

Photo

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.